The contract development and manufacturing organization industry crossed $238 billion in global market value in 2024. By 2032, analysts project […]
The U.S. generic drug market saves $445 billion a year. It also fails, systematically and predictably, to keep the most
The Persistent Problem: Why Hospitals Keep Running Out of Generic Drugs Read Post »
1. What a Generic Drug Actually Is, Legally and Commercially The Regulatory Definition and Why It Is a Legal Construct,
Generic Drug Regulatory Strategy: The Complete Playbook for Pharma IP Teams Read Post »
A field-by-field breakdown of 15 structural flaws that put pharmaceutical IP strategy at risk There is a particular kind of
Why Google Patents Fails Drug Patent Searches — And What to Use Instead Read Post »
The emerging market pharmaceutical story has a simple headline: $500 billion by 2027, compounding at roughly 6.9% annually. What that
Part 1: The Market Reality Behind Analytical Similarity The Patent Cliff Driving a $185 Billion Opportunity The global biosimilar market
A deep-dive for pharma/biotech IP counsel, formulary directors, health economics leads, and institutional investors The Scale of the Problem: Spending
Navigating the Collision of Pharmaceutical Innovation and Managed Care Economics Read Post »
A technical deep-dive into how biosimilar competition is reshaping R&D investment, patent strategy, and lifecycle management across the biopharmaceutical industry.
The Two-Day Gap That Reveals a System Count the days in any calendar quarter. January through March totals 90. April
Sign in or create a free account to read this DrugPatentWatch article
